Eli Lilly and Com…

USUSD

Eli Lilly and Company (US:LLY) — Biotechnology: Pharmaceutical Preparations. Number of exchanges where the company shares trade: 6. On this page — price and chart, dividends, top holders and share count history.

About the company

Website

lilly.com

Sector

Health Care · Biotechnology: Pharmaceutical Preparations

Headquarters

Indianapolis, United States

Management

David A. Ricks

Employees

38 350

Founded

1875

IPO

1970-07-09

Shares outstanding

940.75 M as of 2026-10-26

Year: −0.4% · 3 years: −0.8% · 5 years: −1.6% (excluding splits)

Date	Shares	Change
03.08.2026	941.36 M	−0.04%	no significant change
27.04.2026	941.74 M	−0.2%	buyback
09.02.2026	943.36 M	−0.2%	buyback
27.10.2025	945.38 M	−0.1%	buyback
04.08.2025	946.46 M	−0.1%	buyback
28.04.2025	947.74 M	−0.05%	no significant change
14.02.2025	948.17 M	−0.1%	buyback
25.10.2024	949.32 M	−0.1%	buyback
05.08.2024	950.43 M	—	no significant change
25.04.2024	950.41 M	+0.03%	no significant change
16.02.2024	950.16 M	+0.09%	no significant change
30.10.2023	949.31 M	—	no significant change
03.08.2023	949.3 M	—	no significant change
24.04.2023	949.27 M	−0.1%	buyback
17.02.2023	950.3 M	+0.01%	no significant change

Share count from the company reports. A split is detected by a jump in the count by a whole number of times.

Free float

888.95 M

Market cap

1.2 T USD

Insiders

0.16%

Institutions

85.32%

Industry (SIC)

Pharmaceutical Preparations

Legal form

R0BI

ISIN

US5324571083

LEI

FRDRIPF3EKNDJ2CQJL29

P/E

47.6

P/B

39.4

Payout ratio

21.7%

FCF

19.7 B USD

Payout / FCF

30%

Debt

47.0 B USD

2.1 y of FCF

Dividend streak

54 y

Earnings, FCF and dividends paid — for the 12 months to 30.09.2026 (the company's latest report).

Net income

27.6 B USD 12 mo.

For the 12 months to 30.09.2026 (4 quarters)
Revenue	86.5 B USD
− Expenses	51.7 B USD
Gross profit	72.3 B USD
Net income	27.6 B USD

History by quarter

RevenueExpenses

12.202309.2026

Green above orange is profit (revenue − expenses); red below zero is a loss.

NAV

42.81 USD · P/NAV 33.1

Balance sheet date	30.09.2026
Assets	148 B USD
− Liabilities	108 B USD
= NAV (equity of the company's shareholders)	40.3 B USD
− Goodwill	9.87 B USD
− Intangible assets	18.1 B USD
= Tangible NAV	12.3 B USD
Shares	940 745 031
NAV per share	42.81 USD
Tangible NAV per share	13.09 USD
Share price (LLY)	1 417.54 USD
P/NAV	33.11

NAV history

Balance sheet date	NAV	NAV per share
30.09.2026	40.3 B USD	42.81 USD
30.06.2026	33.9 B USD	35.99 USD
31.03.2026	31.2 B USD	33.13 USD
31.12.2025	26.5 B USD	28.13 USD
30.09.2025	23.8 B USD	25.17 USD
30.06.2025	18.3 B USD	19.31 USD
31.03.2025	15.8 B USD	16.63 USD
31.12.2024	14.3 B USD	15.05 USD

Description

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss; Olumiant; Omvoh; and Taltz. Further, it provides Emgality for migraine prevention and episodic cluster headache; and Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases; BioArctic AB (publ) for new treatment; QurCan Therapeutics Inc for development of PLNP-enabled genetic medicine therapeutics for the treatment of central nervous system and peripheral nervous system; and Abbisko Therapeutics for discovery and development of medicines across multiple targets. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Exchanges and tickers

Exchange	Ticker	Currency	Price	Type
common stock
US USA Stocks	LLY primary	USD	1 417.54 +3.19%	common stock
MI Borsa Italiana (Milan)	1LLY secondary	EUR	1 258.4 -1.18%	common stock
MX Mexican Stock Exchange	LLY secondary	MXN	26 620 +3.17%	common stock
SW SIX Swiss Exchange	LLY secondary	CHF	1 060 +0.00%	common stock
VI Vienna Stock Exchange	LLYC secondary	EUR	1 147.6 +0.19%	common stock
XETRA Xetra	LLY secondary	EUR	1 023.2 -2.29%	common stock
depositary receipt
BA Buenos Aires Stock Exchange	LLY	ARS	33 280 -0.54%	depositary receipt
BK Stock Exchange of Thailand	LLY23	THB	3.88 -1.02%	depositary receipt
BK Stock Exchange of Thailand	LLY80	THB	1.92 -1.54%	depositary receipt
SA B3 Sao Paulo	LILY34	BRL	228.2 -0.95%	depositary receipt
TO Toronto Stock Exchange	LLY	CAD	40.81 -0.54%	depositary receipt

Price

D W M

Hover / tap a day — open, close, high and low prices

Candles

Each candle is one trading day. The thick part runs from the open price to the close price: green — the day closed higher than it opened, red — lower. The thin line runs from the lowest to the highest price of the day. Hover or tap a day to see all four prices.

Dividends

Orange dashed line «ex» — the ex-date: to receive the payment you must hold the shares before this day (shares bought on this day or later come without the dividend). On this day the price often drops by roughly the dividend amount. Blue dashed line «$» — the payment date. Future dates (up to 45 days) are shown on the right on a grey background.

P/E

The share price divided by the company earnings per share for the last 12 months (EPS). It shows how many years the company would need to earn its current profit to «pay back» the price: a lower P/E means the stock is cheaper relative to earnings. The line has its own scale on the left.

For some companies earnings come from their quarterly reports: on the day of a new report P/E jumps (a purple tick at the bottom of the chart), between reports it changes only with the price. For others P/E uses current earnings, so before the latest report it is approximate. If earnings are negative, P/E is not shown.

My position

Visible only to you and only if this stock is among your open portfolio positions (purchases in the same currency as the chart exchange). From each purchase date there is a dashed line at the purchase price, and between it and each day close price — an area: green if the position is in profit, red if at a loss. If you sold part, the remainder is shown: a sale writes off the earliest purchases first. The day tooltip shows how many shares were in the position and the gain or loss in money and %.

Payout yield

The blue dashed curve with its own % scale on the left: for each day — the last payment amount divided by that day close price. That is, what percentage of the share price one payment makes: the price rises — the percentage falls, and vice versa; when the company changes the payment, the curve moves to the new amount. The annual yield is roughly this percentage times the number of payments per year.

Above each «$» mark — the percentage of that payment relative to the price on the payment day (for future ones — relative to the last price, marked «≈»). Only payments in the chart exchange currency are counted.

Dividends

Next ex-date: 2026-11-13 · 1.73 USD (US:LLY)

Per year, US:LLY: 6.92 USD (4 paym.)

Eli Lilly and Company (LLY) pays dividends quarterly. Per year (12 months up to and including the latest announced payment): 6.92 USD per share (payments: 4). That is about 0.49% of the current share price. The next ex-dividend date is 13.11.2026: 1.73 USD per share, paid on 10.12.2026. Uninterrupted dividend history: 54 years.

Ordinary shares

Ex-date	Payment	Amount	%	Type	Ticker
2026-11-13 announced	2026-12-10	1.7300 USD	0.1/0.5 %	quarterly	US:LLY
2026-08-14	2026-09-10	1.7300 USD	0.1/0.6 %	quarterly	US:LLY
2026-05-15	2026-06-10	1.7300 USD	0.2/0.6 %	quarterly	US:LLY
2026-02-13	2026-03-10	1.7300 USD	0.2/0.6 %	quarterly	US:LLY
2025-11-14	2025-12-10	1.5000 USD	0.1/0.6 %	quarterly	US:LLY
2025-08-15	2025-09-10	1.5000 USD	0.2/0.8 %	quarterly	US:LLY
2025-05-16	2025-06-10	1.5000 USD	0.2/0.8 %	quarterly	US:LLY
2025-02-14	2025-03-10	1.5000 USD	0.2/0.6 %	quarterly	US:LLY
2024-11-15	2024-12-10	1.3000 USD	0.2/0.7 %	quarterly	US:LLY
2024-08-15	2024-09-10	1.3000 USD	0.1/0.4 %	quarterly	US:LLY
2024-05-15	2024-06-10	1.3000 USD	0.1/≈0.4 %	quarterly	US:LLY
2024-02-14	2024-03-08	1.3000 USD	0.1/≈0.4 %	quarterly	US:LLY
2023-11-14	2023-12-08	1.1300 USD	0.1/≈0.3 %	quarterly	US:LLY

Depositary receipts

Ex-date	Payment	Amount	%	Type	Ticker
2026-08-14	—	47.088654 ARS	0.1/0.5 %	regular	BA:LLY
2026-05-15	—	47.088654 ARS	0.1/0.7 %	regular	BA:LLY
2026-02-13	—	47.088654 ARS	0.1/0.6 %	regular	BA:LLY
2025-11-14	—	40.82856 ARS	0.1/0.6 %	regular	BA:LLY
2025-08-14	—	40.82856 ARS	0.1/0.6 %	regular	BA:LLY
2025-05-16	—	40.82856 ARS	0.1/0.5 %	regular	BA:LLY
2025-02-14	—	40.82856 ARS	0.1/0.4 %	regular	BA:LLY
2024-11-15	—	35.383938 ARS	0.1/0.4 %	regular	BA:LLY
2024-08-15	—	35.383938 ARS	0.1/1.0 %	regular	BA:LLY
2024-05-15	—	35.383938 ARS	0.1/1.5 %	regular	BA:LLY
2024-02-14	—	35.383938 ARS	0.1/2.0 %	regular	BA:LLY
2023-11-14	—	215.30031 ARS	0.6/2.6 %	regular	BA:LLY
2023-08-14	—	215.30031 ARS	0.6/2.5 %	regular	BA:LLY
2023-05-12	—	215.30031 ARS	0.6/3.0 %	regular	BA:LLY
2023-02-14	—	215.30031 ARS	0.6/2.3 %	regular	BA:LLY
2022-11-14	—	186.72063 ARS	0.6/2.2 %	regular	BA:LLY
2022-08-12	—	186.72063 ARS	0.6/≈2.2 %	regular	BA:LLY
2022-05-13	—	186.72063 ARS	0.6/≈1.6 %	regular	BA:LLY
2022-02-14	—	186.72063 ARS	0.6/≈1.0 %	regular	BA:LLY
2021-11-12	—	161.95157 ARS	0.5/≈0.5 %	regular	BA:LLY

2026-08-14	—	0.004912 THB	0.1/≈0.1 %	regular	BK:LLY23
2026-08-14	—	0.00283 THB	0.1/0.7 %	regular	BK:LLY80
2026-08-14	—	0.062 CAD	0.2/≈0.5 %	regular	TO:LLY
2026-08-13	—	0.205515 BRL	0.1/0.4 %	regular	SA:LILY34
2026-05-15	—	0.00282 THB	0.1/≈0.5 %	regular	BK:LLY80
2026-05-15	—	0.062 CAD	0.2/≈0.3 %	regular	TO:LLY
2026-05-14	—	0.207775 BRL	0.1/0.4 %	regular	SA:LILY34
2026-02-13	—	0.00274 THB	0.1/≈0.4 %	regular	BK:LLY80
2026-02-13	—	0.063 CAD	0.2/≈0.2 %	regular	TO:LLY
2026-02-12	—	0.208252 BRL	0.1/0.4 %	regular	SA:LILY34
2025-11-14	—	0.00244 THB	0.1/≈0.3 %	regular	BK:LLY80
2025-11-13	—	0.189809 BRL	0.1/0.3 %	regular	SA:LILY34
2025-08-15	—	0.00246 THB	0.1/≈0.1 %	regular	BK:LLY80
2025-08-14	—	0.186799 BRL	0.1/0.3 %	regular	SA:LILY34
2025-05-15	—	0.193844 BRL	0.1/0.3 %	regular	SA:LILY34
2025-02-13	—	0.20419 BRL	0.1/0.4 %	regular	SA:LILY34
2024-11-13	—	0.182949 BRL	0.1/0.3 %	regular	SA:LILY34
2024-08-14	—	0.171022 BRL	0.1/0.3 %	regular	SA:LILY34
2024-05-15	—	0.162338 BRL	0.1/0.3 %	regular	SA:LILY34
2024-02-14	—	0.150975 BRL	0.1/0.3 %	regular	SA:LILY34
2023-11-13	—	0.130344 BRL	0.1/0.3 %	regular	SA:LILY34
2023-08-14	—	0.179662 BRL	0.1/0.3 %	regular	SA:LILY34
2023-05-12	—	0.183915 BRL	0.1/0.4 %	regular	SA:LILY34
2023-02-14	—	0.197351 BRL	0.1/0.3 %	regular	SA:LILY34
2022-11-11	—	0.173329 BRL	0.1/0.3 %	regular	SA:LILY34
2022-08-12	—	0.167178 BRL	0.1/≈0.3 %	regular	SA:LILY34
2022-05-13	—	0.16659 BRL	0.1/≈0.2 %	regular	SA:LILY34
2022-02-14	—	0.164065 BRL	0.1/≈0.1 %	regular	SA:LILY34
2021-11-11	—	0.159661 BRL	0.1/≈0.1 %	regular	SA:LILY34

Top holders

Holder	Stake	Shares	Report date
Lilly Endowment, Inc (Be…	9.6%	91.88 M	2026-06-30
Blackrock Inc.	7.17%	67.54 M	2026-06-30
Vanguard Capital Managem…	5.69%	53.53 M	2026-06-30
PNC Financial Services G…	5.45%	51.32 M	2026-06-30
State Street Corporation	3.85%	36.22 M	2026-06-30
FMR, LLC	3.02%	28.46 M	2026-06-30
VANGUARD INDEX FUNDS-Van…	2.86%	26.91 M	2026-06-30
Capital Research Global…	2.22%	20.87 M	2026-06-30
Vanguard Portfolio Manag…	2.22%	20.86 M	2026-06-30
VANGUARD INDEX FUNDS-Van…	2.18%	20.5 M	2026-06-30
Geode Capital Management…	2.16%	20.31 M	2026-06-30
Morgan Stanley	1.72%	16.23 M	2026-06-30
iShares Trust-iShares Co…	1.12%	10.53 M	2026-08-31
Fidelity Concord Street…	1.09%	10.23 M	2026-07-31
SPDR S&P 500 ETF TRUST-S…	1.03%	9.68 M	2026-08-31
VANGUARD INDEX FUNDS-Van…	0.94%	8.87 M	2026-06-30
Growth Fund of America	0.89%	8.36 M	2026-06-30
SELECT SECTOR SPDR TRT-S…	0.6%	5.69 M	2026-08-31
VANGUARD CHESTER FUNDS-V…	0.58%	5.41 M	2026-06-30
Investment Co of America	0.48%	4.52 M	2026-06-30
RICKS DAVID A (Chief Exe…	≈0.08%	708 781	2026-02-09
SKOVRONSKY DANIEL (Offic…	≈0.03%	235 688	2026-02-09
FYRWALD J. ERIK (Directo…	≈0.01%	75 536	2026-09-21
WHITE ANNE E (President)	≈0.01%	74 209	2025-02-10
ALVAREZ RALPH (Director)	≈0.01%	56 596	2026-09-21
JONSSON PATRIK (Officer)	≈0.01%	54 779	2026-08-17
HERNANDEZ EDGARDO (Offic…	≈0%	46 956	2026-09-02
VAN NAARDEN JACOB S. (Of…	≈0%	36 270	2026-02-09
HAKIM ANAT (General Coun…	—	—	2026-08-07